Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
4
Petroleo Brasileiro SA Petrobras
PBR
5
Vale SA
VALE
US Stock MarketDetailed Quotes
PPBT Purple Biotech
- 2.755
- +0.065+2.42%
Close Mar 27 16:00 ET
- 2.722
- -0.034-1.22%
Post 18:40 ET
7.30MMarket Cap-0.55P/E (TTM)
2.925High2.710Low10.75KVolume2.720Open2.690Pre Close30.38KTurnover0.42%Turnover RatioLossP/E (Static)2.65MShares20.60052wk High0.22P/B7.10MFloat Cap2.00052wk Low--Dividend TTM2.58MShs Float1390.000Historical High--Div YieldTTM7.99%Amplitude2.000Historical Low2.825Avg Price1Lot Size
Purple Biotech Stock Forum
Sign in to post a comment
$PMGC Holdings (ELAB.US)$ $Synergy CHC (SNYR.US)$ $Purple Biotech (PPBT.US)$ $Oblong (OBLG.US)$ $Star Equity (STRR.US)$ $Mangoceuticals (MGRX.US)$ $STAK Inc. (STAK.US)$ $LakeShore Biopharma (LSB.US)$ $Kadestone Capital Corp (KDSX.CA)$ $JBDI Holdings (JBDI.US)$ $Pacific Mercantile Bancorp (PNBK.US)$ $Comstock Holding (CHCI.US)$ $VivoPower (VVPR.US)$ $TEN Holdings (XHLD.US)$ $Transcode Therapeutics (RNAZ.US)$
5
5
$Purple Biotech (PPBT.US)$
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
$Purple Biotech (PPBT.US)$
Can Purple Biotech's Newly Patented Cancer Drug Combination Tackle Treatment Resistance?
Can Purple Biotech's Newly Patented Cancer Drug Combination Tackle Treatment Resistance?
$Purple Biotech (PPBT.US)$
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Wednesday, 5th March at 7:00 am
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer
REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-...
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Wednesday, 5th March at 7:00 am
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer
REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-...
2
$Purple Biotech (PPBT.US)$
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity
$Purple Biotech (PPBT.US)$
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...
2
$Purple Biotech (PPBT.US)$
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...
2
1
No comment yet
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Viking Trader : Thanky you
can you explein the colors? Please
103136267 : Hi where do you see this list of stocks with their float?
Stock_Drift OP Viking Trader : Red and Green, it means the same as candles. Its a live ticker.
Stock_Drift OP 103136267 : Google.
Viking Trader : Thanks very much
I hope you get the gretest day at all 